Bekaii-Saab, George, and von Mehren Discuss Pivotal Findings in GIST, TGCT, and RAS/RAF–Mutated Solid Tumors

Drs Bekaii-Saab, George, and von Mehren discuss key efficacy data and patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating the novel ULK inhibitor DCC-3116 in patients with advanced or metastatic RAS or RAF–mutated solid tumors, and how vimiseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.